Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026

What happened: Actuate Therapeutics (NASDAQ: ACTU) announced preclinical data on its Elraglusib Oral Tablet in the B16F10 melanoma model, to be presented in a poster at ENA 2026 in Barcelona. Key numbers: Poster PB-142, session November 18, 2026; symposium runs November 18-20, 2026. FDA cleared the IND in May 2026. Phase 1/2 trial planned to start in Q1 2027. Why it matters: The company says the findings support advancing elraglusib tablets as a single agent in refractory metastatic melanoma, with potential expansion into NSCLC, colorectal, and pancreatic cancer.

Actuate Therapeutics (NASDAQ: ACTU) announced preclinical data on its Elraglusib Oral Tablet in the B16F10 melanoma model, to be presented in a poster at ENA 2026 in Barcelona.

The company says the findings support advancing elraglusib tablets as a single agent in refractory metastatic melanoma, with potential expansion into NSCLC, colorectal, and pancreatic cancer.